Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay ...

The stock looks like a great pick to help turn investors into multimillionaires, given enough time. Everyone should save ...

This stock could make you a fortune in the next two years, or lose you a whole lot of money.

Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...

We're also trying to make sure we look back at some of the trades that are still alive so we can keep you posted. We wrote ...

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Shares of certain biotech firms were rising ahead of market open on Monday on news of the departure of the FDA’s vaccine ...

Eli Casdin, Casdin Capital CEO, joins 'Closing Bell' to discuss the biotech sector, the stocks Casdin favors and much more.